English summaries 43-44/2020 vsk 75 s. 2297 - 2303

Change in the number of people entitled to reimbursement of Parkinson’s disease medications between 1996 and 2015

Margareta AnttilaSirpa HartikainenSanna-Kaisa HerukkaValtteri KaasinenAnna-Maija Tolppanen
Poissulkudiagnoosiryhmien (± 2 vuotta) osuudet kaikista erityiskorvausoikeuden saaneista
Parkinsonin taudin erityiskorvausnumero 110:n saajien iän ja sukupuolijakauman kehitys
Erityiskorvausoikeuden ja Parkinsonin taudin diagnoosin saaneiden osuudet ≥ 35-vuotiaista
Poissulkudiagnoosiryhmien  (± 5 vuotta) osuudet kaikista erityiskorvausoikeuden saaneista
Erityiskorvausoikeuden ja Parkinsonin taudin diagnoosin saaneiden osuudet ≥ 70-vuotiaista
Iän keskiarvo, sukupuoli ja erva-alue ryhmittäin tutkimusvuosina 1996–2015<p/>
Erityiskorvausnumero 110:n saajien diagnoosit ja poissulkukriteerit

Background We studied the change in the number of people entitled to higher special reimbursement of Parkinson’s disease medications during 1996–2015. In addition, we examined whether there were changes in the proportion of people with differential diagnostic and/or exclusion criteria during the same time period.

Methods The national register-based FINPARK cohort contains Finnish people aged ≥ 35 years who were granted the higher special reimbursement for Parkinson’s disease medications in 1996–2015 (n = 29 847). Data were collected from the special reimbursement register and the care register for health care. Exclusion diagnoses were identified with a two-year time window before and after granting the reimbursement.

Results The proportion of people entitled to higher special reimbursement of Parkinson’s disease medications, relative to the Finnish population aged ≥ 35 years, increased by 0.012 percentage points during 1996–2015. Altogether 20–30% of the recipients of reimbursement had exclusion criteria, the most common of which were extrapyramidal and movement disorders and progressive neurodegenerative disorders.

Conclusions There was a small increase in the number of people with Parkinson’s disease in relation to the population aged 35 and over. Nearly one in four of those granted the reimbursement had exclusion criteria within two years of granting the reimbursement. This illustrates the uncertainty of early clinical diagnosis.

Lääkäriliitto Fimnet Lääkärilehti Potilaanlaakarilehti Lääkäripäivät Lääkärikompassi Erikoisalani Lääkäri 2030